Metreleptin (Myalept)
FDA-approved recombinant human leptin analog used to treat the metabolic complications of generalized lipodystrophy.
At a glance
What it is: FDA-approved recombinant human leptin analog used to treat the metabolic complications of generalized lipodystrophy..
Primary research applications:
- Generalized lipodystrophy (FDA-approved indication)
- Severe partial lipodystrophy (off-label / EMA approved)
- Hypothalamic amenorrhea research
Editorial summary: Metreleptin is a recombinant human leptin analog approved for a rare but well-defined indication: lipodystrophy syndromes where adipose tissue cannot produce sufficient endogenous leptin. It is not a treatment for common obesity — leptin replacement was studied extensively for that indication and largely failed because most obese patients have leptin resistance, not leptin deficiency.
- Class / structure
- Recombinant human leptin analog (a single methionine residue added at the N-terminus)
- Half-life
- ~3.8–4.7 hours
- First described
- Approved 2014 (Amryt Pharma / Aegerion / Bristol-Myers Squibb)
- Regulatory status
- FDA-approved 2014 for generalized lipodystrophy; EMA-approved 2018 for generalized and severe partial lipodystrophy
What is Metreleptin?
Metreleptin is a recombinant human leptin analog (with a single N-terminal methionine residue, distinguishing it from native human leptin). It is administered by daily subcutaneous injection to replace the deficient endogenous leptin in patients with lipodystrophy.[1]
Discovery and development
Leptin was discovered in 1994 as the protein product of the ob gene — the molecule whose absence in ob/ob mice produces the dramatic obesity phenotype that defined the leptin-discovery story. The translation to obesity therapy was disappointing: most obese humans have elevated leptin levels and leptin resistance rather than leptin deficiency, and recombinant leptin produces minimal weight loss in common obesity.
The clinical success of recombinant leptin came not from common obesity but from rare lipodystrophy syndromes, where loss of adipose tissue prevents adequate leptin production. In these patients, leptin replacement dramatically improves the severe metabolic dysfunction (hypertriglyceridemia, diabetes, hepatic steatosis) that accompanies the lipodystrophy phenotype. Metreleptin (Myalept) received FDA approval for generalized lipodystrophy in 2014.
Mechanism of action
Leptin signals through the long-form leptin receptor (LepRb) in the hypothalamus, suppressing appetite and increasing energy expenditure. In lipodystrophy, the absence of adipose tissue produces low circulating leptin, which contributes to severe hyperphagia, hypertriglyceridemia, insulin resistance, and hepatic steatosis. Metreleptin replacement restores leptin signaling and substantially improves these metabolic abnormalities.
Pharmacokinetics
Daily subcutaneous injection; plasma half-life of approximately 4 hours. Steady-state levels and clinical effects are sustained with daily dosing.
What the research shows
The peer-reviewed literature on Metreleptin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Treats metabolic complications of generalized lipodystrophy | Phase 3 / approval evidence | Established |
| Treats common obesity through weight loss | Negative trial data; common obesity reflects leptin resistance, not deficiency | Unsupported |
| Restores menstrual cycles in hypothalamic amenorrhea | Mechanistic and clinical-trial evidence | Supported |
| Useful as a general appetite suppressant | Not the indication; leptin resistance limits effect in non-deficient patients | Unsupported |
Reported user experiences
How the research describes administration
Daily subcutaneous injection. Available through restricted distribution program (Myalept REMS) due to risk of antibody formation and lymphoma signal in lipodystrophy patients.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Metreleptin is the textbook example of how an apparent therapeutic failure (recombinant leptin for common obesity) found its real value in a related but distinct indication (leptin replacement in lipodystrophy). For the rare patients who need it, it is dramatically effective; for the much larger population of common obesity, the leptin-replacement story is one of the cleaner negative trials in modern obesity pharmacology and underlies the field's pivot toward GLP-1 and incretin biology.
Frequently asked questions
Can metreleptin be used for ordinary weight loss?
No — and the failure of recombinant leptin in common obesity is part of the foundational evidence for the leptin-resistance model of obesity. Most obese patients have elevated leptin levels, not deficient ones, and adding more does not produce meaningful weight loss.
Why is metreleptin so effective in lipodystrophy?
Because lipodystrophy is genuinely a leptin-deficiency state — the absent adipose tissue produces inadequate leptin, and the metabolic dysfunction (severe hypertriglyceridemia, hepatic steatosis, hyperphagia) reflects that deficiency. Replacing leptin corrects the deficiency.
Is metreleptin used in athletes or biohackers?
It is not a research-peptide-class compound. The cost, restricted distribution, and lack of effect in non-deficient adults make it impractical and ineffective for performance or weight-loss purposes.
References
- Chou K, Perry CM. Metreleptin: first global approval. Drugs. 2013;73(9):989-997. https://pubmed.ncbi.nlm.nih.gov/23740412/
- Oral EA, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570-578. https://pubmed.ncbi.nlm.nih.gov/11856796/
- Heymsfield SB, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568-1575. https://pubmed.ncbi.nlm.nih.gov/10546697/
- Welt CK, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351(10):987-997. https://pubmed.ncbi.nlm.nih.gov/15342807/